- Home
- BLUE
BLUE
bluebird bio Inc.
as 01-21-2025 4:00pm EST
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | SOMERVILLE |
| Market Cap: | 82.2M | IPO Year: | 2013 |
| Target Price: | $49.14 | AVG Volume (30 days): | 292.7K |
| Analyst Decision: | Hold | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -33.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.80 - $38.40 | Next Earning Date: | 11-14-2024 |
| Revenue: | $53,120,000 | Revenue Growth: | 144.50% |
| Revenue Growth (this year): | 145.88% | Revenue Growth (next year): | 239.89% |
Stock Insider Trading Activity of bluebird bio Inc. (BLUE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Obenshain Andrew | BLUE | President and CEO | Jan 6 '25 | Sell | $9.24 | 140 | $1,293.60 | 18,571 | |
| Colvin Richard A | BLUE | Chief Medical Officer | Jan 6 '25 | Sell | $9.24 | 19 | $175.56 | 8,257 | |
| Obenshain Andrew | BLUE | President and CEO | Dec 10 '24 | Sell | $0.42 | 971 | $405.20 | 18,571 | |
| Colvin Richard A | BLUE | Chief Medical Officer | Dec 10 '24 | Sell | $0.42 | 2,824 | $1,178.46 | 8,257 |
Latest bluebird bio Inc. News
BLUE Breaking Stock News: Dive into BLUE Ticker-Specific Updates for Smart Investing
Insider Monkey
24 days ago
bluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now?
Business Wire
a month ago
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Business Wire
a month ago
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
Business Wire
2 months ago
bluebird bio Announces 1-for-20 Reverse Stock Split
Business Wire
2 months ago
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
Benzinga
2 months ago
FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio's Skysona Gene Therapy
Simply Wall St.
2 months ago
bluebird bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Benzinga
2 months ago
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options
Compare BLUE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BLUE bluebird bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.